Biopharma · FDA Approvals · Stock

BMEA Biomea Fusion

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate …

Assets on file: BMF-650, icovamenib

Start live analysis of BMEA Run 8-agent AI analysis All sector events →

Catalyst calendar

Dated catalysts for BMEA, including recently decided ones.

March 2027

Mar 2027

~ Mar 2027

BMEABiomea Fusion

icovamenib: Phase 2 trial NCT07502495 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

June 2027

Jun 2027

~ Jun 2027

BMEABiomea Fusion

icovamenib: Phase 2 trial NCT07502508 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Recent first-hand events

Every first-hand event for BMEA, newest first.

Instant stream — events appear as soon as they are filed.

Decision-gradeMaterialNotableMinor

Oct 20, 2026

03:23 PM

BMEABiomea Fusion

icovamenib · NCT07502508 registry update

countries: {'total_sites': 17, 'us_sites': 17} → {'total_sites': 20, 'us_sites': 20}

Trial registry changeClinicalTrials.gov

Sep 22, 2026

08:01 PM

BMEABiomea Fusion

Biomea Fusion updates BMF-650 Phase 1 GLP-1 topline to October 2026

Biomea Fusion updated the expected timing for topline results from its ongoing Phase 1 GLP-131 trial of BMF-650 in obese, otherwise healthy volunteers. The data readout is now anticipated in October 2026.

Topline resultsSEC 8-K Open record

Nov 4, 2025

09:03 PM

BMEABiomea Fusion

Biomea Fusion reports 52-week Phase II data for icovamenib in T2D

The 52-week follow-up from COVALENT-111 shows icovamenib delivered durable HbA1c reductions of 1.5% in severe insulin-deficient patients and 1.3% in GLP-1 non-responders after only 8–12 weeks of dosing. The safety profile remained comparable to placebo with no treatment-related discontinuations, supporting advancement into two new Phase II trials (COVALENT-211 and COVALENT-212) planned for Q4 2025 / Q1 2026.

Topline resultsSEC 8-K Open record